Home PR Newswire
Friday, May 9, 2025
31.7
C
Bengaluru
My account
Get into your account.
Hot topics
Top 10 Indian Pharma – 2025
India's top 10 pharma companies by market capitalization, offering insights into...
Frontline Managers
Articles by Vivek Hattangadi, Raja Reddy, K. Hariram, Satish Kota, P. S. Parameswaran, Gopal Kishore, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal and Mahendra Kumar Rai
“Sales at Any Cost” is Not Sustainable in the Long Run
For commercial organisations, profits are important. But it cannot be 'at any cost' and certainly not at the cost of human life. As healthcare providers helping to mitigate the pain and misery of millions of human beings, we need to remember that charity begins at home.
What my Sabziwali taught me about the Internet, Mobile Health & Smartphones
It’s very common for a pharma professional having neighbors, friends and relatives to engage in conversation over medicines. One such conversation – a pleasant surprise – which intrigued me to dig deep into internet dynamics was one with the local roadside Sabziwali.
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Hot topics
Digital Transformation and the World of Pharma
A big myth about digital transformation is that it...
Is Pharma’s Business Model like McDonald’s? ...
Is Pharma’s business model like McDonald’s? Doing things over & over again without innovation?
McDonald’s is famous for its Hamburger University, a training facility at the McDonald’s Corporation global headquarters in Chicago, Illinois. It instructs high-potential restaurant managers in restaurant management.
More than 5,000 students attend Hamburger University each year and over 275,000 people have graduated with a degree in Hamburgerology.
Sound familiar? Pharma’s training has been on similar lines – hire people continuously and put them through the grind of mugging up essentials of drugs for diseases that the particular company sells.
While the McDonald’s model is ideal for its business of replication, it has outlived its utility in healthcare and drug companies are in danger of being reduced to mere suppliers of drugs to new digital platform businesses unless they learn to innovate.
The Pill is Now a Commodity – Can ‘Beyond the Pill’ Models Work in India?
The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered.
The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model.
Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison.
‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product.
Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it.
A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it.
The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).
Draft Pharma Policy
Get an in-depth view into the Draft Pharma Policy - MedicinMan does a deep dive with the President of Karnataka Drug and Pharmaceutical Manufacturers Association
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies
April 14, 2025
India’s pharmaceutical industry, a global powerhouse, sends...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Nimesulide – Nice or Not Nise?
Nimesulide Regulatory Status Worldwide
Nimesulide is a non-steroidal anti-inflammatory drug...
Newsletter
Get important news delivered directly to your inbox and stay connected!